Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TB-WIN: Window Prophylaxis for TB Infection Prevention in Children and Adolescents
NCT07086820Recruiting
- Sponsor
- Pontificia Universidad Católica de Chile
- Start
- Oct 2025
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of rifapentine and isoniazid in Tuberculosis (TB) (2 arms), sponsored by Pontificia Universidad Católica de Chile. Primary endpoint: Incidence of new tuberculosis infections (all IGRA conversions) at 12 weeks. Started Oct 2025; status: recruiting.
02
Drugs
rifapentineisoniazid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT07086820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07086820.